​Analyst hikes sales estimates for Biogen’s spinal-disease drug

With earlier-than-expected U.S. approval and a label that includes more patients than previously thought, analysts at Leerink Partners have more than doubled their revenue estimates for the next two years from Biogen ’s new drug for a rare, inherited spinal disease. The Food and Drug Administration late last week approved Spinraza (formerly called nusinersen), the first treatment in the U.S. for spinal muscular atrophy. The drug was developed by Ionis Pharmaceuticals (Nasdaq: IONS), which is based…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Source Type: news